What does the IL-17 Inhibitor Induction procedure involve?

This 12-week outpatient regimen involves subcutaneous injections of secukinumab or ixekizumab, typically administered at weeks 0, 1, 2, 3, and 4, followed by maintenance doses every 4 weeks. These biologic agents block interleukin-17, a key driver of inflammation in psoriasis, to rapidly reduce plaque severity and skin clearance. The loading phase aims to achieve early disease control, with most patients seeing significant improvement within the first month.